Meet the Team!

We are currently looking for enthusiastic and motivated individuals to join our team. We welcome applicants with diverse scientific backgrounds who are interested to learn about cancer cell biology and genomics. We are highly invested in mentoring individuals in our group so that they can develop both scientifically and professionally. 
​
Please email your CV and a description of your interest in our work to Dr. Julia Maxson.

Julia Maxson​
Ph.D., Principal Investigator

Dr. Maxson pursued her undergraduate studies at Scripps College and then completed her Ph.D. in Cell Biology at OHSU in the area of protein trafficking and processing. As a postdoc, Dr. Maxson identified new therapeutic targets in leukemia in the laboratories of Jeff Tyner, and Brian Druker. Notably, she discovered targetable mutations in CSF3R (the receptor for the cytokine GCSF) in the majority of patients with chronic neutrophilic leukemia. Dr. Maxson then moved to Fred Hutchinson Cancer Research Center to pursue the mentored portion of her K99 Pathway to Independence Award on the biochemical mechanisms of aberrant CSF3R activation in leukemia. In 2016, Dr. Maxson moved to the Knight Cancer Institute to establish her laboratory with a focus on leukemia evolution at the genetic and epigenetic level.

Zachary Schonrock
B.A.,  Research Assistant 2

Originally from Salt Lake City, Zachary received his B.A. in Chemistry from Lewis & Clark College in Portland, OR. His senior thesis looked at the effect that environmental factors such as light and natural organic matter influenced the stability of protein-capped gold nanoparticles. Prior to his thesis, he worked in a biochemistry lab at Lewis & Clark isolating the structure of spider venom components, and did medicinal chemistry research at the University of Utah, studying the post-translational modification mechanisms of cyanobactins and fungi. ​In the Maxson lab, his current focus on the mechanisms by which dysregulated epigenetic regulators modify disease biology.

Lauren Maloney
B.S., M.D. Candidate

Lauren graduated from the University of Oregon Clark Honors College in 2016, where she majored in Human Physiology with a minor in chemistry. While in undergrad, she researched neural circuits that mediate auditory cognition and behavioral flexibility, and the biomechanics and proprioception of the upper extremities. After graduation, Lauren worked for Dr. Matthew Taylor and Dr.  Lisa Coussens at the Knight Cancer Institute, focusing on the role of FasL in cancer immunotherapy. Lauren is now a medical student at OHSU, Class of 2022. 

Sarah Carratt
Ph.D., Postdoctoral Scholar

A Seattle-native, Dr. Carratt is thrilled to be back in the Pacific Northwest as a member of the Maxson lab. Dr. Carratt’s passion for research began as an undergraduate at Loyola Marymount University, where she developed an analytical method to use spiders as bioindicators. She continued to investigate environmental toxicants while obtaining her Ph.D. in Pharmacology and Toxicology at the University of California, Davis. Her dissertation research focused on the inhalation toxicity of naphthalene. Sarah is now working on the role of SETBP1 in myeloid malignancies. Her research is funded by a Ruth L. Kirschstein National Research Service Award (NRSA) Individual Postdoctoral Fellowship through the NIH National Cancer Institute. 

​Breanna Maniaci
B.S., Graduate Student

Breanna was born and raised in Alaska, where she attended the University of Alaska Anchorage. There she graduated in 2017 with a B.S. in Chemistry with a minor in Biology. During this time, she studied the protein structure and function of COMMD1 in mammalian copper trafficking under Dr. Jason Burkhead. Through her undergraduate experiences she took an interest in science applied to human disease. She is now a graduate student in the Cancer Biology program at OHSU, and looks forward to expanding her knowledge of myeloid malignancies and the broader topic of cancer.

Daniel Coleman
Ph.D.,  Staff Scientist

Dan grew up in La Pine, Oregon, and earned his BS in Biology from the University of Oregon. After working as a Research Assistant at Marker Gene Technologies, he entered graduate school at Oregon State University, where he studied the role of Retinoid-X-Receptors in melanoma formation. Dan then came to OHSU for his postdoc, where he investigated the potential for targeting BET bromodomain proteins in lethal prostate cancers. Dan's research interests are rooted in investigating transcriptional regulation, with a goal to help make discoveries that can have immediate translational impact.